

Enteric-Zoonotic-Vector Borne Diseases	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	YTD Cases	Current monthly rate ‡ (Jul)			Year to date (YTD) rate ‡ (Jan - Jul)		
														2023	Average (2018-2022)	IRR	2023	Average (2018-2022)	IRR
Amebiasis	0	0	0	0	0	0	0						0	0.0	0.1	0.7	0.0	0.4	0.4
Anaplasmosis***	-	-	-	-	-	-	0						0	0.0	NA	NA	0.0	NA	NA
Babesiosis***	-	-	-	-	-	-	0						0	0.0	NA	NA	0.0	NA	NA
Blastomycosis	1	0	0	0	0	0	0						1	0.0	0.2	0.5	0.5	1.0	0.5
Botulism	0	0	0	0	0	0	0						0	0.0	0.0	NA	0.0	0.0	NA
Brucellosis	0	0	0	0	0	0	0						0	0.0	0.0	NA	0.0	0.0	NA
Campylobacter enteritis	3	0	5	4	6	6	4						28	2.0	4.5	0.5	14.2	13.9	1.0
Carbapenemase-producing enterobacteriaceae (CPE)	0	0	0	0	0	0	0						0	0.0	0.0	NA	0.0	0.3	0.4
Cholera	0	0	0	0	0	0	0						0	0.0	0.0	NA	0.0	0.0	NA
Cryptosporidiosis	0	1	0	1	2	0	1						5	0.5	0.7	0.7	2.5	2.4	1.1
Cyclosporiasis	1	0	0	0	1	3	2						7	1.0	1.8	0.6	3.6	3.0	1.2
Echinococcus Multilocularis	0	0	0	0	0	0	0						0	0.0	0.0	NA	0.0	0.0	NA
Food poisoning, all causes	0	0	0	0	0	0	0						0	0.0	0.0	NA	0.0	0.2	0.5
Giardiasis	3	2	1	2	1	1	2						12	1.0	1.3	0.8	6.1	6.1	1.0
Hepatitis A	0	0	0	0	0	0	0						0	0.0	0.0	NA	0.0	0.1	0.7
Listeriosis	0	0	0	0	0	0	0						0	0.0	0.0	NA	0.0	0.0	NA
Lyme Disease	0	1	1	2	4	12	15						35	7.6	5.1	1.5	17.8	10.7	1.7↑
Paralytic shellfish poisoning (PSP)	0	0	0	0	0	0	0						0	0.0	0.0	NA	0.0	0.0	NA
Paratyphoid Fever	0	0	0	0	0	0	0						0	0.0	0.0	NA	0.0	0.0	NA
Powassan Virus***	-	-	-	-	-	-	0						0	0.0	NA	NA	0.0	NA	NA
Q Fever	0	0	0	0	0	0	0						0	0.0	0.1	0.7	0.0	0.2	0.5
Rabies	0	0	0	0	0	0	0						0	0.0	0.0	NA	0.0	0.0	NA
Salmonellosis	1	6	3	2	0	1	1						14	0.5	1.9	0.3	7.1	7.8	0.9
Shigellosis	0	1	1	0	0	0	0						2	0.0	0.0	NA	1.0	0.1	9.7
Tularemia	0	0	0	0	0	0	0						0	0.0	0.0	NA	0.0	0.1	0.7
Typhoid Fever	0	0	0	0	0	0	0						0	0.0	0.0	NA	0.0	0.0	NA
Verotoxin producing E. coli	0	0	0	0	0	1	1						2	0.5	0.2	2.4	1.0	0.5	1.9
West Nile Virus	0	0	0	0	0	0	0						0	0.0	0.0	NA	0.0	0.0	NA
Yersiniosis	0	0	0	0	0	0	0						0	0.0	0.0	NA	0.0	0.6	0.3

Respiratory Diseases	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	YTD Cases	Current monthly rate ‡ (Jul)			YTD rate ‡ (Jan - Jul)		
														2023	Average (2018-2022)	IRR	2023	Average (2018-2022)	IRR
Coronavirus causing Severe Acute Respiratory Syndrome (COVID-19)*	367	394	268	149	46	23	18						1265	9.1	89.4	0.1↓	641.8	1303.3	0.5↓
Group A streptococcal disease, invasive	2	1	2	8	8	2	2						25	1.0	0.4	2.4	12.7	5.3	2.4↑
Haemophilus influenza a, c, d, e, f, invasive	0	0	0	0	1	0	0						1	0.0	0.2	0.5	0.5	1.0	0.5
Influenza	11	6	16	2	1	1	0						37	0.0	0.2	0.5	18.8	49.0	0.4↓
Legionellosis	0	1	0	0	0	0	0						1	0.0	0.3	0.4	0.5	0.8	0.6

Sexually Transmitted/ Blood Borne Infections	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	YTD Cases	Current monthly rate ‡ (Jul)			YTD rate ‡ (Jan - Jul)		
														2023	Average (2018-2022)	IRR	2023	Average (2018-2022)	IRR
Chlamydia infections	29	17	25	27	25	32	23						178	11.7	13.3	0.9	90.3	90.6	1.0
Gonorrhoea	6	4	4	5	7	6	1						33	0.5	2.6	0.2	16.7	15.5	1.1
Hepatitis B	0	0	0	0	0	1	0						1	0.0	0.1	0.7	0.5	1.3	0.4
Hepatitis C	6	5	8	3	2	4	5						33	2.5	5.5	0.5	16.7	26.5	0.6↓
Syphilis, infectious	3	6	7	4	1	1	4						26	2.0	0.4	4.9	13.2	3.7	3.6↑
Syphilis, other	1	3	0	0	3	0	2						9	1.0	0.4	2.4	4.6	2.7	1.7

AIDS/HIV	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	YTD Cases	Current monthly rate ‡ (Jul)			YTD rate ‡ (Jan - Jul)		
														2023	Average (2018-2022)	IRR	2023	Average (2018-2022)	IRR
AIDS/HIV	0	1	3	1	0	0	0						5	0.0	0.0	NA	2.5	0.6	4.0

TB	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	YTD Cases	Current monthly rate † (Jul)			YTD rate † (Jan - Jul)		
														2023	Average (2018-2022)	IRR	2023	Average (2018-2022)	IRR
Atypical mycobacterial infections	1	0	0	0	1	1	1						4	0.5	0.2	2.4	2.0	2.3	0.9
LTBI	0	0	0	0	2	0	1						3	0.5	0.9	0.5	1.5	4.4	0.3
Tuberculosis	0	0	0	0	0	0	0						0	0.0	0.0	NA	0.0	0.2	0.5

Vaccine Preventable Diseases	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	YTD Cases	Current monthly rate † (Jul)			YTD rate † (Jan - Jul)		
														2023	Average (2018-2022)	IRR	2023	Average (2018-2022)	IRR
Adverse Events Following Immunization (AEFIs)	3	4	5	1	4	0	0						17	0.0	0.9	0.2	8.6	6.7	1.3
COVID-19 vaccine AEFIs*	1	0	0	1	0	2	1						5	0.5	38.6	0.0↓	2.5	214.8	0.0↓
Chickenpox (Varicella)	0	0	0	1	1	0	0						2	0.0	0.0	NA	1.0	0.0	4.9
Diphtheria	0	0	0	0	0	0	0						0	0.0	0.0	NA	0.0	0.0	NA
Encephalitis/Meningitis	0	0	0	0	0	1	0						1	0.0	0.0	NA	0.5	0.6	0.8
Haemophilus influenza b, invasive (Hib)	0	0	0	0	0	0	0						0	0.0	0.0	NA	0.0	0.0	NA
Measles	0	0	0	0	0	0	0						0	0.0	0.0	NA	0.0	0.1	0.7
Meningitis – bacterial	0	0	0	0	0	0	0						0	0.0	0.0	NA	0.0	0.0	NA
Meningitis – other	0	0	0	0	0	0	0						0	0.0	0.0	NA	0.0	0.0	NA
Meningitis – viral	1	0	0	0	0	0	0						1	0.0	0.0	NA	0.5	0.0	2.9
Meningococcal disease, invasive	0	0	0	0	0	0	0						0	0.0	0.0	NA	0.0	0.1	0.7
Mumps	0	0	0	0	0	0	0						0	0.0	0.0	NA	0.0	0.0	NA
Pertussis	0	5	0	0	0	0	0						5	0.0	0.0	NA	2.5	1.4	1.9
Polio	0	0	0	0	0	0	0						0	0.0	0.0	NA	0.0	0.0	NA
Rubella	0	0	0	0	0	0	0						0	0.0	0.0	NA	0.0	0.0	NA
Streptococcus pneumoniae, invasive	4	1	2	2	3	3	1						16	0.5	0.7	0.7	8.1	4.8	1.7
Tetanus	0	0	0	0	0	0	0						0	0.0	0.0	NA	0.0	0.0	NA

Other	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	YTD Cases	Current monthly rate ‡ (Jul)			YTD rate ‡ (Jan - Jul)		
														2023	Average (2018-2022)	IRR	2023	Average (2018-2022)	IRR
Acute flaccid paralysis (AFP)	0	0	0	0	0	0	0						0	0.0	0.0	NA	0.0	0.0	NA
Creutzfeldt-Jakob disease, all type	0	0	0	0	0	0	0						0	0.0	0.0	NA	0.0	0.2	0.5
Leprosy	0	0	0	0	0	0	0						0	0.0	0.0	NA	0.0	0.0	NA
Hemorrhagic Fever – Ebola, Marburg and Other Viral Causes	0	0	0	0	0	0	0						0	0.0	0.0	NA	0.0	0.0	NA
Mpox**	0	0	0	0	0	0	0						0	0.0	0.2	0.5	0.0	0.2	0.5

**Data Notes:** Case definitions for some of the diseases of public health significance have changed over years and may have an impact on the number of cases reported; Current case definitions are provided by MOHLTC through the Infectious Diseases Protocol: [http://www.health.gov.on.ca/en/pro/programs/publichealth/oph\\_standards/infdispro.aspx](http://www.health.gov.on.ca/en/pro/programs/publichealth/oph_standards/infdispro.aspx). Changes to the screening guidelines and testing practices as well as evolving resistance to various first-line treatments have had an impact on case incidence over time, specifically for gonorrhoea and chlamydia. These changes also impact interpretation of comparison between years for specific diseases counts presented. Numbers and rates calculated for previous summary reports may also differ from the current summary due to routine data cleaning; such a change does not reflect an actual change in incidence within the population unless otherwise stated. The data presented in this report represent the most current disease counts in the HKPR District Health Unit and they replace all previous monthly reported statistics.

‡ Rates listed are per 100,000 population; YTD, year-to-date; IRR, incidence rate ratio; † 5-year averages cannot be reported due to the disease becoming newly reportable within the past 5-years and there being no prior reported cases in iPHIS; ↑ Current year or month estimate is significantly greater than the historical estimate based on the IRR 90% confidence interval excluding the null value of 1; ↓ Current year or month estimate is significantly lower than the historical estimate based on the IRR 90% confidence interval excluding the null value of 1. Where any zero-value existed for the current or historical average counts, 0.5 was added to all values included in the IRR calculation to avoid an error from dividing by zero, as per the Haldane-Anscombe correction; the unaltered counts and rates are reported here. NA indicates that there were no cases in the current month/year and no cases in the previous 5-years to compare. \*Cases of COVID-19 and COVID-19 AEFIs use the pervious 3-years (2020-2022) for comparison; \*\*Cases of Mpox use the pervious year (2022) for comparison.

**Source:** iPHIS, August 16, 2023; CCM (COVID-19 cases and AEFIs) August 14, 2023.

- Please note that the numbers of cases reported in this document are based on Diagnosing Health Unit, *not* Responsible Health Unit. This means that the case counts presented reflect the incidence of disease within HKPR District Health Unit; the case counts are *not* a complete reflection of the caseload within the HKPR District Health Unit. The cases are based on “Accurate Episode Date” and hence there is a chance that some cases, specifically chronic infections such as Hepatitis C, TB and some STIs, may appear in the report earlier than when they were reported to the Health Unit.
- In this report, cases of Tuberculosis are reported by month of symptom onset date (accurate episode date) not diagnosis date. Counts over the same time-period may vary from those reported by Public Health Ontario and the Ontario Ministry of Health and Long-Term Care.
- As of January 22<sup>nd</sup>, 2021, diseases caused by a novel coronavirus, including Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS), were added as Diseases of Public Health Significance.
- \*\*\*As of July 1<sup>st</sup>, 2023, Anaplasmosis, Babesiosis, and Powassan Virus were added as Diseases of Public Health Significance.



**Foundational Standards Division**

www.hkpr.on.ca • 1-866-888-4577